Literature DB >> 20687491

Amyotrophic lateral sclerosis.

J Jefferson P Perry1, David S Shin, John A Tainer.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a common neurological disorder that results in loss of motor neurons, leading to a rapidly progressive form of muscle paralysis that is fatal. There is no available cure and current therapies only provide minimal benefit at best. The disease is predominantly sporadic and until very recently only the Cu,Zn superoxide dismutase (Cu,ZnSOD), which is involved in a small number of sporadic cases and a larger component of familial ones, have been analyzed in any detail. Here we describe the clinical aspects of ALS and highlight the genetics and molecular mechanisms behind the disease. We discuss the current understanding and controversies of how mutations in Cu,ZnSOD may cause the disease. We also focus on the recent discovery that mutations in either TDP-43 or FUS/TLS, which are both involved in DNA/RNA synthesis, are likely the cause behind many cases of ALS that are not linked to Cu,ZnSOD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687491     DOI: 10.1007/978-1-4419-6448-9_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  13 in total

1.  The preclinical discovery of amyotrophic lateral sclerosis drugs.

Authors:  Marcie A Glicksman
Journal:  Expert Opin Drug Discov       Date:  2011-10-25       Impact factor: 6.098

Review 2.  The role of mitochondria in neurodegenerative diseases.

Authors:  Massimiliano Filosto; Mauro Scarpelli; Maria Sofia Cotelli; Valentina Vielmi; Alice Todeschini; Valeria Gregorelli; Paola Tonin; Giuliano Tomelleri; Alessandro Padovani
Journal:  J Neurol       Date:  2011-05-22       Impact factor: 4.849

3.  An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies.

Authors:  Grant Coan; Cassie S Mitchell
Journal:  Neurodegener Dis       Date:  2015-07-16       Impact factor: 2.977

4.  Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency.

Authors:  Kambiz N Alavian; Steven I Dworetzky; Laura Bonanni; Ping Zhang; Silvio Sacchetti; Maria A Mariggio; Marco Onofrj; Astrid Thomas; Hongmei Li; Jamie E Mangold; Armando P Signore; Ulrike Demarco; Damon R Demady; Panah Nabili; Emma Lazrove; Peter J S Smith; Valentin K Gribkoff; Elizabeth A Jonas
Journal:  Brain Res       Date:  2012-01-28       Impact factor: 3.252

5.  Monoclonal antibodies to discriminate the EF hand containing calcium binding adaptor proteins EFhd1 and EFhd2.

Authors:  Sebastian Brachs; Christiane Lang; Rolf Buslei; Pavitra Purohit; Barbara Fürnrohr; Hubert Kalbacher; Hans-Martin Jäck; Dirk Mielenz
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2013-08

6.  Fraternal twins: Swiprosin-1/EFhd2 and Swiprosin-2/EFhd1, two homologous EF-hand containing calcium binding adaptor proteins with distinct functions.

Authors:  Sebastian Dütting; Sebastian Brachs; Dirk Mielenz
Journal:  Cell Commun Signal       Date:  2011-01-18       Impact factor: 5.712

7.  Alteration in superoxide dismutase 1 causes oxidative stress and p38 MAPK activation following RVFV infection.

Authors:  Aarthi Narayanan; Taissia Popova; Michael Turell; Jessica Kidd; Jessica Chertow; Serguei G Popov; Charles Bailey; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

8.  Structural and molecular insights into the mechanism of action of human angiogenin-ALS variants in neurons.

Authors:  Nethaji Thiyagarajan; Ross Ferguson; Vasanta Subramanian; K Ravi Acharya
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

9.  Prediction of functional loss of human angiogenin mutants associated with ALS by molecular dynamics simulations.

Authors:  Aditya K Padhi; Bhyravabhotla Jayaram; James Gomes
Journal:  Sci Rep       Date:  2013-02-07       Impact factor: 4.379

10.  The protective and therapeutic function of small heat shock proteins in neurological diseases.

Authors:  Sara E Brownell; Rachel A Becker; Lawrence Steinman
Journal:  Front Immunol       Date:  2012-05-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.